<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">therapeutic</journal-id><journal-title-group><journal-title xml:lang="ru">Южно-Российский журнал терапевтической практики</journal-title><trans-title-group xml:lang="en"><trans-title>South Russian Journal of Therapeutic Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2712-8156</issn><issn pub-type="epub">3033-8344</issn><publisher><publisher-name>РостГМУ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21886/2712-8156-2021-2-4-79-84</article-id><article-id custom-type="elpub" pub-id-type="custom">therapeutic-189</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛЕКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LECTURES</subject></subj-group></article-categories><title-group><article-title>Роль диацереинов в лечении остеоартрита с позиции новой парадигмы патогенеза (лекция для практикующих врачей)</article-title><trans-title-group xml:lang="en"><trans-title>The role of diacereins in the treatment of osteoarthritis from the point of view of a new paradigm of pathogenesis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5275-3261</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Елисеева</surname><given-names>Л. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Eliseeva</surname><given-names>L. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елисеева Людмила Николаевна, доктор медицинских наук, профессор, заведующий кафедрой факультетской терапии</p><p>Краснодар</p></bio><bio xml:lang="en"><p>Liudmila N. Eliseeva, Dr. Sci. (Med), Prof, Head of the Department of Faculty Therapy</p><p>Krasnodar</p></bio><email xlink:type="simple">Yeliseyeva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8383-5032</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карташова</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kartashova</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Светлана Владимировна Карташова, ассистент кафедры факультетской терапии</p><p>Краснодар</p></bio><bio xml:lang="en"><p>Svetlana V. Kartashova, Assistant of the Department of Faculty Therapy</p><p>Krasnodar</p></bio><email xlink:type="simple">malyvinasv@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kuban State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>29</day><month>11</month><year>2021</year></pub-date><volume>2</volume><issue>4</issue><fpage>79</fpage><lpage>84</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Елисеева Л.Н., Карташова С.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Елисеева Л.Н., Карташова С.В.</copyright-holder><copyright-holder xml:lang="en">Eliseeva L.N., Kartashova S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.therapeutic-j.ru/jour/article/view/189">https://www.therapeutic-j.ru/jour/article/view/189</self-uri><abstract><p>Среди наиболее распространённых заболеваний человечества у пациентов старшей возрастной группы выделяется суставная патология с дегенеративными изменениями гиалинового хряща, значительно ограничивающая функциональную активность локомоторного аппарата. Бурное развитие экспериментальных научных исследований в последние десятилетия позволило пересмотреть представления о патогенезе данного процесса с подтверждением ведущей роли воспаления в развитии функциональных и структурных повреждений при данном заболевании. Эти новые данные аргументировали изменение названия болезни с «остеоартроза» на «остеоартрит» и обосновали положительные эффекты отдельных лекарственных препаратов. В предлагаемом лекционном материале освещены основные вопросы современного представления о патогенезе остеоартрита и дополнительные преимущества использования препаратов из группы диацереинов в связи с их противовоспалительным и хондропротективным эффектом.</p></abstract><trans-abstract xml:lang="en"><p>Among the most common diseases of humanity in patients of the older age group, there is an articular pathology with degenerative changes in the hyaline cartilage, which significantly limits the functional activity of the locomotor apparatus. The rapid development of experimental scientific research in recent decades has made it possible to revise the concept of the pathogenesis of this process with confirmation of the leading role of inflammation in the development of functional and structural damage in this disease. These new data supported the change in the name of the disease from “osteoarthros” to “osteoarthritis” and justified the positive effects of individual drugs. The proposed lecture material discloses the topic of the modern understanding of the pathogenesis of osteoarthritis and the additional benefits of using drugs from the diacerein group due to their anti‑inflammatory and chondroprotective effect.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>остеоартрит</kwd><kwd>остеоартроз</kwd><kwd>диацереины</kwd></kwd-group><kwd-group xml:lang="en"><kwd>osteoarthritis</kwd><kwd>osteoarthritis</kwd><kwd>diacereins</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Балабанова P.M. Роль иммунного воспаления в патогенезе остеоартроза, возможности коррекции иммунных нарушений. Современная ревматология. 2011;4:74-78. Elibrary ID: 17109327</mixed-citation><mixed-citation xml:lang="en">Bibliography</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Балабанова Р.М. Эрдес Ш.Ф. Динамика распространенности ревматических заболеваний, входящих в XIII класс МКБ-10, в популяции взрослого населения Российской Федерации за 2000-2010 гг. Научно-практическая ревматология. 2012;3 (50):10-12. Elibrary ID: 18365050</mixed-citation><mixed-citation xml:lang="en">Balabanova P.M. The role of immune inflammation in the pathogenesis of osteoarthritis, the possibility of correcting immune disorders. Modern rheumatology. 2011;4:74-78  (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377(9783):211526. DOI: 10.1016/S0140-6736(11)60243-2.</mixed-citation><mixed-citation xml:lang="en">Balabanova R.M. Erdes Sh.F. Trends in the prevalence of rheumatic diseases in ICD-10 in the adult population of the Russian Federation over 2000-2010. Nauchno-prakticheskaya revmatologiya. 2012;3 (50):10-12. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Кашеварова Н.Г., Алексеева Л.И., Аникин С.Г., Дёмин Н.В., Смирнов А.В., Насонов Е.Л. Остеоартроз коленных суставов: факторы риска прогрессирования заболевания суставов при пятилетнем проспективном заболевании. Вопросы организации и информатизации здравоохранения. 2016;S:144-9. Elibrary ID: 29855353</mixed-citation><mixed-citation xml:lang="en">Bijlsma J, Berenbaum F, Lafeber P. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377(9783): 2115-26. doi:10.1016/S0140-6736(11)60243-2;</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Martel-Pelletier J, Roubille C, Abram F, Hochberg MC, Dorais M, Delorme P, et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis. 2015;74(3):547-56. DOI: 10.1136/annrheumdis-2013-203906.</mixed-citation><mixed-citation xml:lang="en">Kashevarova NG, Alekseeva LI, Anikin SG, et al. Osteoarthritis of the knee: risk factors for the progression of joint disease in a five-year prospective disease. Proceedings of the III Eurasian Congress of rheumatologists, (Minsk, Republic of Belarus, 26-27 may 2016). Voprosy organizatsii i informatizatsii zdravookhraneniya. 2016;Suppl:144-9. (InRuss.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med. 2006;166(17):1899-906. DOI: 10.1001/archinte.166.17.1899. Erratum in: Arch Intern Med. 2007;167(5):444. PMID: 17000948.</mixed-citation><mixed-citation xml:lang="en">Martin-Pelletier J, Roubille C, Abram F, et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis. 2015 Mar;74(3):547–56. doi: 10.1136/annrheumdis-2013-203906. Epub 2013 Dec 13;</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Martel-Pelletier J., Lajeunesse D., Pelletier J.P. Etiopathogenesis of osteoarthritis. In: Arthritis and Allied Conditions: A Textbook of Rheumatology. W.J. Koopman, L.W. Moreland (eds). Baltimore: lippincott, Wikings W., 2005:2199–296</mixed-citation><mixed-citation xml:lang="en">Rintelen B., Neumann K.,Leeb B.F. A meta-analysis of controlled clinical studies with Diacerhein in the treatment osteoarthritis. Arch. Intern.Med., 2006,166,1899-906;</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(Pt 1):1-20. DOI: 10.1042/BJ20030407.</mixed-citation><mixed-citation xml:lang="en">Martel-Pelletier J., Lajeunesse D., Pelletier J.P. Etiopathogenesis of osteoarthritis. In: Arthritis and Allied Conditions: A Textbook of Rheumatology. W.J. Koopman, L.W. Moreland (eds). Baltimore: lippincott, Wikings W., 2005:2199–296</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Филатова Е.С., Туровская Е.Ф., Алексеева Л.И. Комплексная терапия хронического болевого синдрома у пациентов с остеоартритом коленных суставов. Эффективная фармакотерапия. 2018;(19):18-25. Elibrary ID: 35215682</mixed-citation><mixed-citation xml:lang="en">Heinrich P.C., Behrmann I., Haan S. et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374(Pt 1):1–20</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ведение больных с остеоартритом и коморбидностью в общей врачебной практике: клинические рекомендации консенсуса экспертов Российской Федерации. Сост. А.В. Наумов, Л.И. Алексеева; 2015.</mixed-citation><mixed-citation xml:lang="en">Filatova ES, Turovskaya EF, Alekseeva LI. Complex therapy of chronic pain syndrome in patients with knee osteoarthritis. Effektivnaya farmakoterapiya. 2018;(19): 18-25. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">De Girolamo L, Kon E, Filardo G, Marmotti AG, Soler F, Peretti GM, et al. Regenerative approaches for the treatment of early OA. Knee Surg Sports Traumatol Arthrosc. 2016;24(6):182635. DOI: 10.1007/s00167-016-4125-y.</mixed-citation><mixed-citation xml:lang="en">Management of patients with osteoarthritis and comorbidity in general medical practice: clinical recommendations of the consensus of experts of the Russian Federation. - M., 2015. 41 s. (In Russ)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеева Л.И. Обновление клинических рекомендаций по лечению больных остеоартритом 2019 года. Русский медицинский журнал. 2019;27(4):2-6. Elibrary ID: 38502084</mixed-citation><mixed-citation xml:lang="en">De Girolamo L, Kon E, Filardo G, et al. Regenerative approaches for the treatment of early OA. Knee Surg Sports Traumatol Arthrosc. 2016 Jun;24(6):1826-35. doi: 10.1007/s00167-016-4125-y. Epub 2016 Apr 27.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Altman RD, Farrokhyar F, Fierlinger A, Niazi F, Rosen J. Analysis for Prognosti Factors from a Database for the Intra-Articular Hyaluronic Acid (Euflexxa) Treatment for Osteoarthritis of the Knee. Cartilage. 2016;7(3):229-37. DOI: 10.1177/1947603515620890.</mixed-citation><mixed-citation xml:lang="en">Алексеева Л.И. Обновление клинических рекомендаций по лечению больных остеоартритом 2019 года. Русский медицинский журнал. 2019;4:2-6. [Alekseeva L.I. Update of clinical guidelines for the treatment of patients with osteoarthritis 2019. Russian Medical Journal –2019;4:2-6. (in Russ.)];</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т., Мартынов А.И., Яхно Н.Н., Арутюнов Г.П., и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56:1-29. DOI: 10.14412/1995-44842018-1-29</mixed-citation><mixed-citation xml:lang="en">Altman RD, Farrokhyar F, Fierlinger A, et al. Analysis for Prognostic Factors from a Database for the Intra-Articular Hyaluronic Acid (Euflexxa) Treatment for Osteoarthritis of the Knee. Cartilage. 2016;7(3):229-37. https://doi.org/10.1177/1947603515620890</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Pan J, Wang B, Li W, Zhou X, Scherr T, Yang Y, et al. Elevated cross-talk between subchondral bone and cartilage in osteoarthritic joints. Bone. 2012;51(2):212-7. DOI: 10.1016/j.Bone.2011.11.030.</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(S1):1-29. (In Russ.)]. doi: doi.org/10.14412/rjtao20180</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Honvo G, Reginster JY, Rannou F, Rygaert X, Geerinck A, Rabenda V, et al. Safety of Intra-articular Hyaluronic Acid Injections in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(Suppl 1):101-127. DOI: 10.1007/s40266-019-00657-w.</mixed-citation><mixed-citation xml:lang="en">Pan J, Wang B, Li W, Zhou X, Scherr T, Yang Y, Price C, Wang L Elevated cross-talk between subchondral bone and cartilage in osteoarthritic joints. Bone. 2012 Aug;51(2):212-7. doi: 10.1016/j.bone.2011.11.030. Epub 2011 Dec 16)</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Roumie CL, Choma NN, Kaltenbach L, Mitchel EF Jr, Arbogast PG, Griffin MR. Non-aspirin nsaids, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf. 2009;18(11):1053-63. DOI: 10.1002/pds.1820.</mixed-citation><mixed-citation xml:lang="en">Honvo G., Reginster J.Y., Rannou F. et al. Safety of intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and metaanalysis. Drugs Aging. 2019;36 (Suppl. 1):45–46;</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Pariente A, Scotti L, et al. Stroke risk and nsaids: a systematic review of observational studies. Pharmacoepidemiol Drug Saf. 2011;20(12):1225-36. DOI: 10.1002/pds.2227.</mixed-citation><mixed-citation xml:lang="en">Roumie C, Choma N, Kaltenbach L, et al. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1053-63. doi: 10.1002/pds.1820</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Barkin RL, Beckerman M, Blum SL, Clark FM, Koh EK, Wu DS. Should nonsteroidal anti-inflammatory drugs (nsaids) be prescribed to the older adult? Drugs Aging. 2010;27(10):775-89. DOI: 10.2165/11539430-000000000-00000.</mixed-citation><mixed-citation xml:lang="en">Varas-Lorenzo C., Riera-Guardia N., Calingaert B. et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011;20(12):1225–36. DOI: 10.1002/pds.2227.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. Pain Med. 2009;10(6):1062-83. DOI: 10.1111/j.1526-4637.2009.00699.x.</mixed-citation><mixed-citation xml:lang="en">Barkin R.L., Beckerman M., Blum S.L. et al. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging 2010;27(10): 775–89. DOI: 10.2165/11539430- 000000000-00000</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kingsbury SR, Hensor EM, Walsh CA, Hochberg MC, Conaghan PG. How do people with knee osteoarthritis use osteoarthritis pain medications and does this change over time? Data from the Osteoarthritis Initiative. Arthritis Res Ther. 2013;15(5):R106. DOI: 10.1186/ar4286.</mixed-citation><mixed-citation xml:lang="en">American Geriatrics Society Panel on the Pharmacological. Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. Pain Med 2009;10(6):1062–83. DOI: 10.1111/j.1526-4637.2009.00699.x</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Шостак Н.А., Клименко А.А., Демидова Н.А., Аничков Д.А. Безопасность селективных нестероидных противовоспалительных препаратов: анализ данных последних лет. Клиницист. 2020;14(1-2):91-99. DOI: 10.17650/1818-8338-2020-14-1-2-91-99</mixed-citation><mixed-citation xml:lang="en">Kingsbury S.R., Hensor E.M., Walsh C.A. et al. How do people with knee osteoarthritis use osteoarthritis pain medications and does this change over time? Data from the Osteoarthritis Initiative. Arthritis Res Ther 2013;15(5):106. DOI: 10.1186/ar4286</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Мартынов А. И. Наумов А.В., Вёрткин А.Л., Алексеева Л.И., Дыдыкина П.С. Ведение больных остеоартритом с коморбидностью в общей врачебной практике: мнение экспертов, основанное на доказательной медицине. Лечащий врач. 2015;(4):39–45. Elibrary ID: 23280110</mixed-citation><mixed-citation xml:lang="en">Shostak N.A., Klimenko A.A., Demidova N.A., Anichkov D.A. Safety of selective non-steroidal anti-inflammatory drugs: analysis of the last years data. The Clinician. 2020;14(1-2):91-99. (In Russ.) https://doi.org/10.17650/1818-8338-2020-14-1-2-91-99</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kongtharvonskul J, Anothaisintawee T, mcevoy M, Attia J, Woratanarat P, Thakkinstian A. Efficacy and safety of glucosamine, diacerein, and nsaids in osteoarthritis knee: a systematic review and network meta-analysis. Eur J Med Res. 2015;20(1):24. DOI: 10.1186/s40001-015-0115-7.</mixed-citation><mixed-citation xml:lang="en">Martynov A.I., Naumov A.V., Vyortkin A.L., Alekseeva L.I., Dydykina P.S. Vedenie bolnyh osteoartritom s komorbidnostyu v obshej vrachebnoj praktike: mnenie ekspertov, osnovannoe na dokazatelnoj medicine. Lechashij vrach. 2015;4:39–45. (in Russ)</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеева Л.И., Кашеварова Н.Г., Таскина Е.А., Шарапова Е.П., Аникин С.Г., Короткова Т.А., и др. Эффективность и безопасность диацереина у пациентов с остеоартритом коленных суставов. Современная ревматология. 2017;11(3):50-57. DOI: 10.14412/1996-7012-2017-3-50-57.</mixed-citation><mixed-citation xml:lang="en">Kongtharvonskul J., Anothaisintawee T., McEvoy M. et al. Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis. Eur J Med Res. 2015;20(1):24</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Балабанова Р.М., Kaptaeva A.K. Артродарин новый препарат для патогенетической терапии остеоартроза. Научнопрактическая ревматология. 2009;47(2):49-53. DOI: 10.14412/1995-4484-2009-459.</mixed-citation><mixed-citation xml:lang="en">Alekseeva L.I., Kashevarova N.G., Taskina E.A., Sharapova E.P., Anikin S.G., Korotkova T.A., Strebkova E.A. Efficacy and safety of diacerein in patients with knee osteoarthritis. Modern Rheumatology Journal. 2017;11(3):50-57. (In Russ.) https://doi.org/10.14412/1996-7012-2017-3-50-57.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев А.Е., Алексеева Л.И. Оценка переносимости диацереина в реальной клинической практике. Результаты исследования РОКАДА (Ретроспективная Оценка Клинических Аспектов применения Диафлекса при остеоартрозе). Научно-практическая ревматология. 2015;53(2):169–174. DOI: 10.14412/1995-4484-2015-169-174.</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Alekseeva LI. Assessment of the tolerance of diacerein in real clinical practice. Results of the ROKADA study (Retrospective Assessment of the Clinical Aspects of Diaflex Application in OsteoArthrosis). Scientific and practical rheumatology. 2015; 53 (2): 169-174 (In Russ.)]  doi.org/10.14412/1995-4484-2015-169-174</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Mendes A.F., Caramona M.M., de Carvalho A.P. et al. Diacerhein and Rhein reduce the ICE-induced IL-1b -induced nuclear factorkappa B activation by inhibiting the degradation of inhibitor kappa B –alfa. Pharmacol.Toxicol. 2002;91:22-8</mixed-citation><mixed-citation xml:lang="en">Mendes A.F., Caramona M.M., de Carvalho A.P. et al. Diacerhein and Rhein reduce the ICE-induced IL-1b -induced nuclear factor- kappa B activation by inhibiting the degradation of inhibitor kappa B –alfa. Pharmacol.Toxicol., 2002;91:22-8</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Martin G, Bogdanowicz P, Domagala F, Ficheux H, Pujol JP. Rhein inhibits interleukin-1 beta-induced activation of MEK/ ERK pathway and DNA binding of NF-kappa B and AP-1 in chondrocytes cultured in hypoxia: a potential mechanism for its disease-modifying effect in osteoarthritis. Inflammation. 2003;27(4):233-46. DOI: 10.1023/a:1025040631514.</mixed-citation><mixed-citation xml:lang="en">Martin G., Bogdanowicz P., Domagala F. et al. Rhein inhibits IL-1b –induced activation of MEK/ERK pathway and DNA binding of NF-kappa B and AP-1 in chondrocytes cultured in hypoxia: potential mechanism for its disease-modifying effect in osteoarthritis. Inflammation, 2003;27:233-46.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Moldovan F, Pelletier JP, Jolicoeur FC, Cloutier JM, martelpelletier J. Diacerhein and rhein reduce the ICE-induced IL1beta and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis Cartilage. 2000;8(3):186-96. DOI: 10.1053/joca.1999.0289.</mixed-citation><mixed-citation xml:lang="en">Moldovan F., Jolicoeur F.C., Martel-Pelletier J. Diacerhein and Rhein reduce the ICE-induced IL-1b and IL-18 activation in human osteoarthritis cartilage. Osteoarthr.Cart. 2000;8:186-96</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Felisaz N, Boumediene K, Ghayor C, Herrouin JF, Bogdanowicz P, Galerra P, et al. Stimulating effect of diacerein on TGF-beta1 and beta2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthritis Cartilage. 1999;7(3):25564. DOI: 10.1053/joca.1998.0199.</mixed-citation><mixed-citation xml:lang="en">Pelletier J.P., Mineau F., Boileau C. et al. Diacerhein reduce the level of cartilage chondrocyte DNA fragmentation and death in experimental dog osteoarthritis cartilage at the same time that in inhibits caspase-3 and inducible nitric oxide synthase. Clin Exp Rheum. 2003;21:171–177.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Pelletier JP, Mineau F, Boileau C, Martel-Pelletier J. Diacerein reduces the level of cartilage chondrocyte DNA fragmentation and death in experimental dog osteoarthritic cartilage at the Same time that it inhibits caspase-3 and inducible nitric oxide synthase. Clin Exp Rheumatol. 2003;21(2):171-7.</mixed-citation><mixed-citation xml:lang="en">Tamura T., Shirai N., Kosaka N. Et al. Pharmacological studies of Diacerhein in animal models of inflammation, arthritis and bone resorbtion. Eur.J.Pharm.,2002;448:81-7;</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеева Л.И., Кашеварова Н.Г., Таскина Е.А., Шарапова Е.П., Аникин С.Г., Короткова Т.А., и др. Эффективность и безопасность диацереина у пациентов со стеоартритом коленных суставов. Современная ревматология. 2017;11(3):50-57. DOI: 10.14412/1996-7012-2017-3-50-57</mixed-citation><mixed-citation xml:lang="en">Alekseeva L.I., Kashevarova N.G., Taskina E.A., Sharapova E.P., Anikin S.G., Korotkova T.A., Strebkova E.A. Efficacy and safety of diacerein in patients with knee osteoarthritis. Modern Rheumatology Journal. 2017;11(3):50-57. (In Russ.) https://doi.org/10.14412/1996-7012-2017-3-50-57</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Tamura T, Shirai T, Kosaka N, Ohmori K, Takafumi N. Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. Eur J Pharmacol. 2002;448(1):81-7. DOI: 10.1016/s0014-2999(02)01898-8.</mixed-citation><mixed-citation xml:lang="en">Zheng W.J.,Tang F.L.,Li J. et al. Evaluation of  efficacy and safety of Diacerhein in knee osteoarthritis in Chinese patients. Chin.Med.Sci.,2006;21:75-80</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng WJ, Tang FL, Li J, Zhang FC, Li ZG, Su Y, et al. Evaluation of efficacy and safety of diacerein in knee osteoarthritis in Chinese patients. Chin Med Sci J. 2006;21(2):75-80. PMID: 16845791.</mixed-citation><mixed-citation xml:lang="en">Wiffen PJ, Kalso EA, et al. Topical analgesics for acute and chronic pain in adults – an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017 May 12;5:CD008609. doi: 10.1002/14651858. CD008609.pub2;</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Derry S, Wiffen PJ, Kalso EA, Bell RF, Aldington D, Phillips T, et al. Topical analgesics for acute and chronic pain in adults an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017;5(5):CD008609. DOI: 10.1002/14651858.CD008609.pub2.</mixed-citation><mixed-citation xml:lang="en">Instructions for the drug. Directory of medicines Vidal</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
